

REGULATORY PRESS RELEASE

Stockholm December 18, 2019

Extraordinary general meeting in Karessa Pharma on 18 December 2019

An extraordinary general meeting in Karessa Pharma Holding AB (publ) ("Karessa") was held today, on 18 December 2019, in Hamilton Advokatbyrå's office, Hamngatan 27, in Stockholm whereby the shareholders made the following resolution.

Approval of merger plan

The extraordinary general meeting resolved, by required majority, to approve the merger plan adopted by the board of directors of Karessa and Klaria Pharma AB (publ) ("Klaria") on 5 November 2019, according to which the merger is undertaken by way of absorption, with Klaria as the absorbing company and Karessa as the transferring company. According to the merger plan, the exchange ratio for the merger consideration has been determined in such way that each share in the Karessa shall be exchanged for 0,6032 new shares in Klaria.

The merger is expected to be registered with the Swedish Companies Registration Office in the first quarter 2020 and will result in the dissolution of Karessa, whereby all of Karessa's assets and liabilities will be transferred to Klaria. Settlement of the merger consideration will take place following the Swedish Companies Registration Office's registration of the merger.

This is information that Klaria Pharma Holding AB (publ) and Karessa Pharma Holding AB (publ) are required to disclose in accordance with the EU Market Abuse Regulation. The information was submitted for publication, by the agency of the contact persons below, on 18 december 2019, at 13:45.

For more information, please contact:

Mats Nilsson, VD Karessa Pharma Holding AB (publ)

Tel: +46-8-768 22 33

mats.nilsson@karessa.se

About Karessa Pharma Holding AB

Karessa is a Swedish pharmaceutical company with the goal of developing products based on a patented drug delivery platform with direct absorption of active substances from the oral cavity to the bloodstream. For more information, visit karessa.se. Certified Advisor: FNCA Sweden AB, info@fnca.se, +46-8-528 00 399.